Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00881335
Other study ID # SHDC12007211-O
Secondary ID
Status Completed
Phase N/A
First received April 14, 2009
Last updated June 25, 2012
Start date April 2009
Est. completion date May 2009

Study information

Verified date June 2012
Source Tongji University
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the clinical outcome and safety of flutter mucus clearance devices in elders of gerocomium.


Description:

Respiratory diseases are still increasing in the elderly population. The fluttering mucus clearance technique is expected to be a physical assisting therapy enhancing airway secretion clearance but needs more clinical randomized, controlled trial evidence.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date May 2009
Est. primary completion date May 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 85 Years and older
Eligibility Inclusion Criteria:

- available to perform the device, the elders in geracomium

- male and female

- aging 85 years or more

Exclusion Criteria:

- not available to perform the procedure

- untreated pneumothorax

- diffusion interstitial lung disease

- acute coronary syndrome

- third stage hypertension

- advanced cancer

- severe heart, liver, renal, blood system and endocrine system dysfunction

- noninvasive mechanical ventilation

- active hemoptysis

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Device:
flutter mucus clearance device
five minutes every sessions, three sessions per day

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tongji University

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Cases With Fever (Body Temperature Reach 38 Degree Celsius or Higher) up to 28 days Yes
Primary MPEF,Mean Peak Expiratory Flow indicators of pulmonary function, for example, PEF(unit of measurement:Liter per minute) All subjects sit upright in a chair and instructed to perform the pulmonary function test. Repeat the test until three reproducible acceptable results are obtained. Spirometry was performed at the first day of baseline and the 28th day of our study. up to 28 days Yes
Primary FEV1, Forced Expiratory Volume at First Second indicators of pulmonary function, for example, FEV1(unit of measurement:Liter)
All subjects sit upright in a chair and instructed to perform the pulmonary function test. Repeat the test until three reproducible acceptable results are obtained. Spirometry was performed at the first day of baseline and the 28th day of our study.
up to 28 days Yes
Primary FVC, Forced Vital Capacity indicators of pulmonary function, for example, FVC(unit of measurement:Liter)
All subjects sit upright in a chair and instructed to perform the pulmonary function test. Repeat the test until three reproducible acceptable results are obtained. Spirometry was performed at the first day of baseline and the 28th day of our study.
up to 28 days Yes
Primary FEV1/FVC%, the Ratio of FEV1 to FVC indicators of pulmonary function,
All subjects sit upright in a chair and instructed to perform the pulmonary function test. Repeat the test until three reproducible acceptable results are obtained. Spirometry was performed at the first day of baseline and the 28th day of our study.
up to 28 days Yes
Secondary Number of Cases With Antibiotics Therapy antibiotics therapy is the indicators of pulmonary infection up to 28 days Yes
Secondary Number of Cases With Hospital Visit up to 28 days Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Active, not recruiting NCT02504697 - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Terminated NCT00524095 - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Phase 2
Completed NCT00210249 - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Completed NCT00023114 - p450 Mediated Lung Toxicity N/A
Recruiting NCT06056882 - Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
Completed NCT03994848 - Incentive Spirometry Prehabilitation Study N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Withdrawn NCT05100160 - Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial) Phase 3
Completed NCT03229473 - Fall Risk Assessment in COPD
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04996693 - On Dose Efficiency of Modern CT-scanners in Chest Scans N/A
Recruiting NCT04996173 - Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis) N/A
Completed NCT04601545 - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method N/A
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Recruiting NCT02862418 - Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)